0000000000643838

AUTHOR

Riccardo M. Inciardi

showing 3 related works from this author

Treatment decision making in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: State of the art

2014

No abstract available

medicine.medical_specialtymedicine.medical_treatmentDecision MakingCardiomyopathySudden deathImplantable cardioverter-defibrillatorAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden death; Arrhythmogenic Right Ventricular Dysplasia; Decision Making; HumansAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden deathInternal medicinemedicineHumansIn patientIntensive care medicineArrhythmogenic Right Ventricular DysplasiaRadiofrequency catheter ablationbusiness.industrySudden deathImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareArrhythmogenic right ventricular dysplasiaAntiarrhythmic drugsManagementAntiarrhythmic drugRadiofrequency catheter ablationCardiologyCardiac transplantationTreatment decision makingCardiology and Cardiovascular Medicinebusiness
researchProduct

Therapeutic management in Sicilian patients with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy and focus on the role of implanta…

2014

Arrhythmogenic Right Ventrticular Dysplasia/Cardiomyopathy(ARVD/C) is an inherited cardiomyopathy characterized by right ven-tricularmyocytelosswithfibrofattyreplacement,ahighriskofventric-ular arrhythmias (VA) and sudden cardiac death (SCD) [1]. Preventionof SCD represents the most important management strategy and theachievement of this target can be reached by different therapeuticstrategies including implantable cardioverter-defibrillator (ICD)implantation, pharmacologic therapy, catheter ablation of ventriculartachycardia (VT) and cardiac transplantation [2,3]. The aim of thisstudy is to examine the outcome of the different therapies adopted ina group of affected patients, focusing on th…

AdultMalemedicine.medical_specialtyTime FactorsCardiomyopathymedicine.medical_treatmentCardiomyopathyCatheter ablationImplantable cardioverterdefibrillatorSudden deathInternal medicinemedicineHumansMedical managementSicilySurvival rateArrhythmogenic Right Ventricular DysplasiaCardiomyopathy; Implantable cardioverterdefibrillator; Medical management; Predictors; Sudden deathSudden deathbusiness.industryPrognosisImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareDefibrillators ImplantableArrhythmogenic right ventricular dysplasiaSurvival RateTransplantationDeath Sudden CardiacTreatment OutcomeHeart failureCardiologyFemaleMorbidityCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesPredictorInternational Journal of Cardiology
researchProduct

Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.

2016

Background: Chemotherapy cardiotoxicity is an emerging problem and it is very important to prevent cardiac dysfunction caused by anticancer drugs. The aim of this study was to assess the alterations of the cardiac function induced by chemotherapy in a follow-up of 2 years and to evaluate the cardioprotective role of angiotensin-converting enzyme inhibitors (ACEIs) in the prevention of cardiac dysfunction. Methods: A prospective study was carried out using patients with breast cancer (85 women; median age 57W12years) and other inclusion and exclusion criteria. On the basis of treatment, patients were divided into six groups: fluorouracil-epirubicincyclophosphamide, FEC (group A); FEC and tra…

Cardiac function curveAdultmedicine.medical_specialtyCardiotonic Agentsmedicine.medical_treatmentAngiotensin-Converting Enzyme InhibitorsBreast Neoplasms030204 cardiovascular system & hematologyBioinformaticsCardiac dysfunctionAngiotensin-converting enzyme inhibitor; Cardiotoxicity; Chemotherapy; Prevention; Tissue Doppler imaging; Adult; Aged; Aged 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Early Diagnosis; Echocardiography Doppler; Female; Follow-Up Studies; Humans; Middle Aged; Prospective Studies03 medical and health sciencesTissue Doppler imaging0302 clinical medicinecardiac toxicity anti cancer drugs cardiac dysfunctionInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overMedicineChemotherapyHumansProspective StudiesAgedAged 80 and overCardiotoxicityChemotherapybusiness.industryPreventionFollow up studiesDopplerGeneral MedicineMiddle AgedCardiotoxicityEchocardiography DopplerClinical trialEarly DiagnosisAngiotensin-converting enzyme inhibitorEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct